Trevi Therapeutics
TRVI
217 hedge funds and large institutions have $2.76B invested in Trevi Therapeutics in 2026 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 89 increasing their positions, 59 reducing their positions, and 20 closing their positions.
1,718% more call options, than puts
Call options by funds: $26.4M | Put options by funds: $1.45M
115% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 20
71% more capital invested
Capital invested by funds: $1.61B → $2.76B (+$1.15B)
51% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 59
33% more funds holding in top 10
Funds holding in top 10: 9 → 12 (+3)
10% more funds holding
Funds holding: 198 → 217 (+19)
0.14% less ownership
Funds ownership: 105.09% → 104.96% (-0.14%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$65.8M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$44.8M |
| 3 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$30.5M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$22.2M |
| 5 |
Barclays
London,
United Kingdom
|
+$15.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$24.1M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$18.8M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$17.6M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$17.5M |
| 5 |
OCA
Octagon Capital Advisors
New York
|
-$17M |
TRVI Hedge Fund Activity: Q2 2026 in Review
217 of the 3,514 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q2 2026, worth a combined $2.76B — up 71% from $1.61B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new TRVI positions and 20 closed out — a net gain of 23 holders — while 89 added to existing stakes and 59 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $65.8M. The largest seller was Viking Global Investors, cutting an estimated $24.1M.
- 217 institutional investors held Trevi Therapeutics (TRVI) as of Q2 2026, up from 198 in Q1 2026.
- Funds reported $2.76B of Trevi Therapeutics stock for Q2 2026, up 71% quarter-over-quarter.
- 43 funds opened new Trevi Therapeutics positions in Q2 2026 and 20 closed out, a net change of +23 holders.
- The largest Trevi Therapeutics buyer in Q2 2026 was Fidelity Investments, an estimated $65.8M added.
- The largest Trevi Therapeutics seller in Q2 2026 was Viking Global Investors, an estimated $24.1M sold.
Based on aggregated 13F filings for Q2 2026.